{"product_id":"solara-swot-analysis","title":"Solara Active Pharma Sciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSolara Active Pharma Sciences shows resilient API manufacturing capabilities and a growing global footprint, yet faces regulatory and margin pressures from pricing-sensitive markets; our full SWOT dissects competitive advantages, pipeline risks, and scalability levers to inform strategic choices. Purchase the complete SWOT analysis to receive a professionally formatted, editable Word and Excel package with research-backed insights and actionable recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Ibuprofen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolara is among the world’s largest ibuprofen producers, with vertically integrated plants that cut COGS and improve margins; ibuprofen made ~18% of Solara Active Pharma Sciences’ revenue in FY2024 (₹X billion) and underpins steady cash flow into 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Regulatory Compliance and Certifications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolara Active Pharma operates multiple plants approved by USFDA, EUGMP, and EDQM, with 18 USFDA approvals and 12 EDQM certificates as of Dec 2025, ensuring access to regulated markets.\u003c\/p\u003e\n\u003cp\u003eConsistent successful inspections create a high barrier to entry, protecting revenue streams—formulations for the US\/EU accounted for ~46% of 2024 API revenues.\u003c\/p\u003e\n\u003cp\u003eThe compliance framework underpins 55 active Drug Master Files (DMFs) and 22 Certificates of Suitability (CEPs) across oncology, cardiovascular, and CNS therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified API Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSolara Active Pharma Sciences has expanded beyond flagship drugs to \u0026gt;60 commercial APIs across niche and high-growth areas, cutting concentration risk and cushioning price erosion in any single molecule; as of FY2024 the API mix drove ~35% of revenues, up from 28% in FY2022. The lineup spans complex molecules in anthelmintics, antipsychotics, and hyperkalemia, letting Solara serve varied customer needs and target higher-margin specialty segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Research and Development Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSolara Active Pharma Sciences invests roughly 5–6% of FY2024 revenue in R\u0026amp;D to improve processes and create cost-efficient generic APIs, focusing on higher-margin, low-volume molecules rather than bulk commodities.\u003c\/p\u003e\n\u003cp\u003eDedicated research centers have sped DMF (drug master file) filings—25+ DMFs by end-2025—supporting a steady commercialization pipeline and helping gross margins stay above peer averages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend ~5–6% of FY2024 revenue\u003c\/li\u003e\n\u003cli\u003eFocus: high-value, low-volume APIs\u003c\/li\u003e\n\u003cli\u003e25+ DMFs filed by end-2025\u003c\/li\u003e\n\u003cli\u003eImproved gross margins vs bulk peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Global Customer Relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSolara Active Pharma Sciences has long-term partnerships with top generics and innovators, supplying APIs to clients including firms in the US, EU and India; these ties helped generate reported revenue of INR 27.7 billion (US$335m) in FY2024.\u003c\/p\u003e\n\u003cp\u003eHigh switching costs stem from stringent supplier qualification—multi-year audits and regulatory filings—making Solara a preferred, de-risking partner for global supply chains.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term contracts with top generics\/innovators\u003c\/li\u003e\n\u003cli\u003eHigh switching costs: multi-year qualification\u003c\/li\u003e\n\u003cli\u003eReputation for quality drove FY2024 revenue INR 27.7B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolara: Vertically Integrated, Low-Cost API Leader—Ibuprofen Focus, Strong Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSolara is a low-cost, vertically integrated leader in ibuprofen (~18% of FY2024 revenue; INR 4.99B of INR 27.7B), with 18 USFDA and 12 EDQM approvals (Dec 2025), 55 DMFs and 22 CEPs, \u0026gt;60 commercial APIs, R\u0026amp;D ~5–6% of FY2024 revenue, and long-term contracts that sustain margin premium and steady cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Revenue\u003c\/td\u003e\n\u003ctd\u003eINR 27.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIbuprofen share\u003c\/td\u003e\n\u003ctd\u003e18% (INR 4.99B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSFDA \/ EDQM\u003c\/td\u003e\n\u003ctd\u003e18 \/ 12 (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMFs \/ CEPs\u003c\/td\u003e\n\u003ctd\u003e55 \/ 22\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial APIs\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e5–6% of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Solara Active Pharma Sciences, outlining its core strengths, internal weaknesses, external opportunities, and potential threats to assess strategic positioning and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Solara Active Pharma Sciences for quick strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Financial Performance Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolara Active Pharma Sciences has shown inconsistent profitability and margin swings—net margin ranged from -2.4% in FY2022 to 6.8% in FY2024—driven by operational restructuring and market headwinds.\u003c\/p\u003e\n\u003cp\u003eInvestors stayed cautious as ROE fell to 3.5% in FY2023 after integration challenges, pressuring valuation multiples to trade below peers (FY2024 P\/E ~12x vs peer median ~18x).\u003c\/p\u003e\n\u003cp\u003eBy Q3 2025 EBITDA margins improved to 11.2%, but the legacy of volatility still weighs on investor confidence and keeps multiples suppressed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Product Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite diversification efforts, about 28% of Solara Active Pharma Sciences’ FY2024 revenue came from Ibuprofen and a few other APIs, so any 20% price drop or demand shock in these molecules could cut consolidated revenue by ~5–6% and pressure margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSolara Active Pharma Sciences has carried substantial debt—net debt stood at INR 12.4 billion as of FY2024 (ended Mar 31, 2024)—taken to fund acquisitions and capacity expansion.\u003c\/p\u003e\n\u003cp\u003eHigh interest costs (~INR 850 million in FY2024) compress net margins and reduce free cash flow for R\u0026amp;D and biotech investments.\u003c\/p\u003e\n\u003cp\u003eManagement cites bringing debt-to-equity toward 0.8 as a priority to protect credit metrics and fund future growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWorking Capital Intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe API business is capital-intensive, forcing Solara Active Pharma Sciences to hold large inventories and offer long credit to export clients; FY2024 receivables days for Indian API peers averaged ~90–120 days, which likely stretches Solara’s cash conversion cycle and tightens liquidity.\u003c\/p\u003e\n\u003cp\u003eStretched working capital can compress operating cash flow—Solara reported negative operating cash flow in parts of 2023–24 for the sector—and requires continuous supply‑chain and collections optimization to avoid refinancing or margin pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh inventory needs raise funding cost\u003c\/li\u003e\n\u003cli\u003eReceivables 90–120 days vs payables shorter\u003c\/li\u003e\n\u003cli\u003eOCF volatility in 2023–24 for API firms\u003c\/li\u003e\n\u003cli\u003eRequires tight supply‑chain and collections\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Pricing Pressure in Regulated Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa large share of solara active pharma sciences revenue comes from regulated markets eu india government tenders where generic competition and pricing pressure are intense fy2024 exports made up about sales exposing margins to buyer consolidation. buying groups public-health reforms push api prices down squeezing upstream suppliers who have limited pass-through power. continuous cost cuts process innovation needed offset a reported bps annual gross-margin erosion in some segments but sustaining that pace is hard.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~68% exports (FY2024) concentrate pricing risk\u003c\/li\u003e\n\u003cli\u003eBuyer consolidation \u0026amp; tenders compress margins\u003c\/li\u003e\n\u003cli\u003e120–180 bps annual gross-margin pressure in segments\u003c\/li\u003e\n\u003cli\u003eRequires sustained capex and R\u0026amp;D for cost cuts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh leverage, export concentration \u0026amp; stretched working capital weigh on margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInconsistent profits (net margin -2.4% FY2022 → 6.8% FY2024), low ROE (3.5% FY2023), high net debt INR 12.4bn (FY2024) with INR 850m interest cost, revenue concentration: 28% on few APIs, 68% exports (FY2024) exposing pricing risk, stretched working capital (receivables ~90–120 days) and capex-heavy model pressuring cash flow and valuation multiples.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet margin FY2024\u003c\/td\u003e\n\u003ctd\u003e6.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eROE FY2023\u003c\/td\u003e\n\u003ctd\u003e3.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003eINR 12.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest cost FY2024\u003c\/td\u003e\n\u003ctd\u003eINR 850m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration\u003c\/td\u003e\n\u003ctd\u003e28% top APIs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports FY2024\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReceivables days\u003c\/td\u003e\n\u003ctd\u003e90–120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSolara Active Pharma Sciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752232825209,"sku":"solara-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/solara-swot-analysis.png?v=1772238578","url":"https:\/\/growthsharematrix.com\/products\/solara-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}